Navigation Links
Therapure Biopharma Inc. Awarded US Government Contract for Development of Anti-Nerve Gas Agent
Date:6/11/2013

Mississauga, ON (PRWEB) June 11, 2013

Therapure Biopharma Inc., a contract development and manufacturing organization (CDMO) of biotherapeutics, is pleased to announce the company will participate as a subcontractor for DynPort Vaccine Company LLC (DVC), a CSC company, that was awarded a US cost-plus-fixed-fee contract with a maximum value of $157.3 million (prime contract number W911QY-13-C-0056) by the US Department of Defense (DoD) to support the development of a prophylactic countermeasure to prevent the effects of organophosphorus nerve agent poisoning.

Therapure’s subcontract under the above prime contract includes process optimization as well as manufacture of all clinical and nonclinical materials (drug product) to support DVC’s contract to develop, test and obtain the US Food and Drug Administration (FDA) approval for human plasma-derived butyrylcholinesterase (HuBChE), a blood plasma protein that binds and inactivates nerve agents. Mr. Nick Green, Therapure’s President and Chief Executive Officer, said: “We are delighted to partner with DVC to develop and manufacture medical counter measures for the US Department of Defense as part of a defense strategy against a wide range of nerve gases. Therapure successfully completed a rigorous selection and approval process to serve as the manufacturing subcontractor under the prime contract, which is a testament to the Company’s standards and capabilities in biomanufacturing. It is an honor to be part of this very critical initiative to protect US Servicemen and women.”

Any opinions, findings and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the U.S. Department of Defense, Department of the Army, Chemical Biological Medical Systems Joint Project Management Office (CBMS JPMO), Medical Identification and Treatment Systems Joint Product Management Office (MITS JPMO).

ABOUT THERAPURE BIOPHARMA INC.
Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies and packages therapeutic proteins. As a CDMO, Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop innovative and efficient solutions to advance client products from discovery to market. Therapure’s 130,000 sq. ft. facility includes manufacturing, research and quality-control laboratories and is built to U.S. FDA, EMA, MHRA and Health Canada standards.

For more information, please visit: http://www.therapurebio.com.

Company Contact:
Dina Iezzi
Director, Marketing and Special Projects
diezzi(at)therapurebio(dot)com
905-286-6270

Read the full story at http://www.prweb.com/releases/2013/6/prweb10824674.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Monoclonal Antibodies Market Dealmaking in Biopharma Industry Analyzed in New Research Report at ReportsnReports.com
2. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
3. $9 million grant awarded to UH to study, treat learning disabilities
4. Kessler Foundation scientist awarded $554,000 for multiple sclerosis employment research
5. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
6. Grant awarded to help improve problem-solving skills for deaf and hard-of-hearing students
7. Southeast program to fight diabetes awarded nearly $10 million by HHS
8. Clemson professor awarded nearly $600,000 4-year grant to study language of plants
9. 29 Johns Hopkins stem cell researchers awarded funding
10. Einstein awarded $6 million grant to develop new TB vaccine against drug-resistant strains
11. FirstVitals Health and Wellness, Inc. awarded $4 Million CMS Innovation Grant for Unique Telehealth Diabetes Progam Focused on Glycemic Control and Prevention of Diabetic Foot Complications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... ... Hamlin Dental Group and Dr. Hamid Reza, dentist in North Hollywood ... of February, patients who visit Hamlin Dental Group will receive a ticket for a ... the Cheesecake Factory. , Tickets are available for routine dental visits and other ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... an approved content provider for the National Institute for Health and Care ... social care-related organizations in the National Health Service (NHS) to search, order and ...
(Date:2/23/2017)... ... ... Dr. David Mahon leads Siena Dental, a comprehensive dental practice located at ... Top Patient Rated Henderson Dentist by Find Local Doctors earlier this year. ... dentists who have earned high ratings and superior patient reviews from multiple credible sources. ...
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, a global data ... that Premier Research, a leading clinical development service provider, has selected ERT’s Trial ... complex, due in part to an array of circumstances including the use of ...
(Date:2/23/2017)... NJ (PRWEB) , ... February 23, 2017 , ... ... the pre-eminent publication and community for those in the fight against cancer, has ... important in their success. HRA will release top-line findings in a webinar, ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , February 23, 2017 According ... by Product (X-ray Imaging Digital, Analog), MRI (Closed, Open), ... MSK, Cardiology, Oncology), End User (Hospitals, Imaging Centers) - ... studies the global market over the forecast period of ... ~USD 36.43 Billion by 2021, at a CAGR of ...
(Date:2/23/2017)... -- As National Nutrition Month approaches, USA Medical is providing ... people live healthier lives by providing discounts on ... all 50 states including:  Texas Prescription Assistance Program ... Assistance Program . USA Medical also shares ... nutritious eating habits: Limit ...
(Date:2/23/2017)... , Feb. 23, 2017 LG Innotek today announced ... for sterilization applications. As its sterilization performance is 1.5 times higher ... short wavelength ultraviolet rays in the range of 200 -- 280nm, allowing ... of bacteria by destroying their DNA. LG Innotek,s product emits UV ... ...
Breaking Medicine Technology: